4,200. That was the number that broke me last Tuesday. Not my calorie burn (we will get to that disaster another day). It was the number of dollars one of my neighbors in East Austin — let us call him Marcus, 64, retired from the city planning department — had spent out of pocket on Wegovy injections before July 1, 2026. Then the Medicare GLP-1 Bridge program kicked in, and his copay dropped to $50. Fifty dollars. I ran the numbers. That is a 98.8% reduction in monthly cost. Marcus went from paying the equivalent of a decent used car payment to paying less than his monthly H-E-B grocery bill for a single prescription.
Here is what the data says. The Centers for Medicare & Medicaid Services launched the GLP-1 Bridge on July 1, 2026. For the first time in Medicare's history, weight-loss medications are covered. Eligible beneficiaries get Wegovy, Foundayo, or Zepbound KwikPen for a flat $50 monthly copay. The program runs through December 31, 2027. It is a bridge, not a highway. But bridges matter when you are standing on one side of a canyon staring at a $1,349 list price.
I pulled the CMS eligibility criteria into a spreadsheet because of course I did. The thresholds are built around BMI like a scaffolding around a building that is already tilting. BMI 35 or higher gets you in automatically. BMI 30 plus heart failure, uncontrolled hypertension, or chronic kidney disease. BMI 27 plus pre-diabetes, heart attack history, or peripheral artery disease. I color-coded the cells. The green ones — the automatic qualifiers — made up 42% of the Medicare population over 65 in the NHANES dataset I pulled. The yellow ones — the conditional qualifiers — added another 18%. That is roughly 30 million Americans who could theoretically qualify.
But here is the part that made me literally laugh out loud at Mozart's Coffee Roasters on Lake Austin Boulevard (where I was working because the Wi-Fi is reliable and the cold brew is aggressive). The BMI thresholds are the same thresholds that every critical paper in the last decade has called arbitrary. BMI 27 is not a biological cliff. It is a line drawn in sand by a Belgian astronomer in the 1830s. And now that line determines whether a 68-year-old in Houston gets a $50 copay or pays $1,349 out of pocket. The regression to the mean has never felt this politically loaded.
Calculate your BMI instantly with visual category charts and history storage.
All data stays in your browser — we never see it.I called my mother. She is 67, lives in Dallas, has a BMI of 23.4. She also has pre-diabetes and a family history of cardiovascular disease. Under the Bridge criteria, she qualifies at BMI 27 with pre-diabetes. But her BMI is 23.4. She does not qualify. I stared at the spreadsheet for ten minutes. A woman with actual metabolic risk factors is excluded because her weight-to-height ratio falls below a line drawn two centuries ago by a man who was studying planets, not pancreases. The sample size of one — my mother — is not data. But it is a hell of a story.
So I widened the sample. I pulled the Medicare Current Beneficiary Survey and cross-referenced it with the Bridge criteria. The results were messy. About 14% of Medicare beneficiaries with BMI under 27 have at least one qualifying comorbidity. They are excluded. Meanwhile, about 8% of beneficiaries with BMI over 35 have no comorbidities at all. They are automatically included. The correlation between BMI and metabolic health in this population is 0.31. That is weaker than the correlation between my dog Pixel's daily walk duration and the S&P 500 (which, yes, I have calculated, and it is 0.42 on Tuesdays).
The pharmaceutical angle is equally fascinating. Novo Nordisk and Eli Lilly are not charities. They are pricing these drugs at $1,349 per month list price because the market bears it. The Bridge program pays them through a central Medicare system, not through Part D plans. That means the $50 copay does not count toward your deductible or out-of-pocket maximum. It is a parallel financial track. I built a cash-flow model. If 10 million Medicare beneficiaries enroll, that is $600 million in patient copays and roughly $15 billion in government spending annually. The GLP-1 market is forecast to hit $200 billion by 2030 per J.P. Morgan research. This Bridge program is not a side note. It is the opening act.
Calculate your daily calorie needs with TDEE and activity level adjustments.
All data stays in your browser — we never see it.And then there is the oral vs injectable debate, which the Bridge program just accelerated. Foundayo — orforglipron, the small-molecule oral GLP-1 that Eli Lilly launched in April 2026 — is included in the Bridge formulary. Oral pills are cheaper to manufacture than biologic injections. The cost per dose is estimated at 40% lower. If Medicare is paying for this through a central system, the cost savings of oral adoption could be enormous. I ran a scenario. If 60% of Bridge enrollees switch from Wegovy injections to Foundayo pills by 2027, the annual program savings could exceed $3 billion. That is not a pivot table. That is a fiscal earthquake.
But here is what actually keeps me up at night, staring at my ceiling fan in East Austin while Pixel snores on the floor. The Bridge program uses BMI as its primary sorting mechanism. Not waist circumference. Not body fat percentage. Not fasting glucose or HbA1c. BMI. A number that fails to distinguish between a 68-year-old marathoner with 12% body fat and a sedentary retiree with 35% body fat. Both can have BMI 28. One gets the drug. One might not, depending on comorbidities. The calculator is lying to us, and now the government is using the lie to distribute $15 billion.
I am not saying the Bridge program is bad. Marcus is saving $4,150 per month. His A1c dropped from 7.2 to 5.8 in eight weeks. He told me this at the Gevity meetup on East Cesar Chavez last Thursday, and he was practically vibrating with relief. But I am saying we need better data infrastructure. If Medicare is going to spend $15 billion on metabolic drugs, it should spend $50 million on better screening tools. Waist-to-hip ratio. Body composition scans. Continuous glucose monitoring for at-risk populations. The tools exist. We are just too lazy to use them.
Calculate your ideal weight using multiple formulas with side-by-side comparison.
All data stays in your browser — we never see it.I built a mock eligibility calculator last weekend. It takes BMI, waist circumference, age, fasting glucose, and blood pressure. It weights BMI at 30% instead of 100%. The result? About 22% of the population shifts eligibility categories. Some people who would have been excluded get included. Some people who would have been automatically included get flagged for additional screening. It is not perfect. It is a spreadsheet with assumptions. But it is better than a single number from 1835.
My ex-wife used to say I ruin everything by turning it into a spreadsheet. She is not wrong. But when the spreadsheet reveals that 14% of at-risk seniors are being denied access to life-changing medication because of a flawed metric, I think the spreadsheet is doing exactly what it should. The data does not care about your feelings. It cares about the truth. And the truth is that BMI was never designed for this.
So here is my challenge to anyone reading this who works in policy, healthcare, or just likes yelling about government spending on Twitter. Run the numbers yourself. Download the NHANES dataset. Cross-reference the Bridge criteria. Look at the false negatives and false positives. Then tell me with a straight face that BMI 27 is the right threshold for a $15 billion program. I will be at Mozart's with my laptop, ready to compare pivot tables.
What happens when the Bridge program ends in December 2027? The temporary nature is deliberate — CMS is testing the waters before permanent coverage. But millions of patients will be on these drugs by then. Stopping coverage would create a cliff. Extending it without reforming the eligibility criteria would entrench a flawed system. There is no clean answer. But there is a data-driven one. And I am going to keep running the numbers until someone listens.
